公开(公告)号：US20070078188A1

公开(公告)日：2007-04-05

申请号：US11407327

申请日：2006-04-20

申请人： Mark Currie ,  Steven Jones ,  Chrisantha Senanayake ,  Zhi-Hiu Lu

发明人： Mark Currie ,  Steven Jones ,  Chrisantha Senanayake ,  Zhi-Hiu Lu

IPC分类号： A61K31/137

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/56 ,  A61K2300/00

摘要： The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE2. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.

摘要翻译： 本发明包括使用外消旋和对映异构纯的去甲氟西汀以及药物组合物，药物单位剂型和包含外消旋和对映异构纯的去甲氟西汀的试剂盒的方法。 特别地，本发明包括抑制或降低PGE 2 2的产生的方法。 本发明还包括治疗或预防患者炎症的方法，以及治疗或预防疾病或病症的方法，所述疾病或病症例如但不限于自身免疫疾病，关节炎，神经系统疾病，炎性疾病，纤维肌痛，疼痛 由炎症，神经性疼痛和癌症引起。

公开(公告)号：US20060148775A1

公开(公告)日：2006-07-06

申请号：US11364659

申请日：2006-02-28

申请人： Mark Currie ,  Steve Jones ,  Paul Grover ,  Chris Sennayake ,  Q. Fang

发明人： Mark Currie ,  Steve Jones ,  Paul Grover ,  Chris Sennayake ,  Q. Fang

IPC分类号： A61K31/573

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  Y10S514/87 ,  A61K2300/00

摘要： Compositions containing β2 adrenergic agonists in combination with carbonates and carbamates of the formula and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.

摘要翻译： 公开了含有β2肾上腺素能激动剂与下式的碳酸酯和氨基甲酸酯并与相关的类固醇碳酸酯和氨基甲酸酯组合的组合物。 该组合物可用于治疗支气管痉挛，用于诱发支气管扩张和治疗鼻炎，哮喘和慢性阻塞性肺疾病（COPD）和炎性疾病，特别是通过吸入治疗。

公开(公告)号：US20060014982A1

公开(公告)日：2006-01-19

申请号：US11220891

申请日：2005-09-07

申请人： Thomas Jerussi ,  Qun Fang ,  Mark Currie

发明人： Thomas Jerussi ,  Qun Fang ,  Mark Currie

IPC分类号： A61K31/137 ,  C07C211/38

CPC分类号： C07C211/42 ,  C07B2200/07 ,  C07C2602/10 ,  C07C2602/28

摘要： Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.